BREAST-CANCER SCREENING PROGRAMS - THE DEVELOPMENT OF A MONITORING AND EVALUATION SYSTEM
BREAST-CANCER SCREENING PROGRAMS - THE DEVELOPMENT OF A MONITORING AND EVALUATION SYSTEM
复制标题
DOI：
10.1038/bjc.1989.203
复制
发表时间：
1989-06-01
影响因子：
8.8
通讯作者：
KHAW, KT
中科院分区：
文献类型：
--
作者：
DAY, NE;WILLIAMS, DRR;KHAW, KT
必须密切监测乳房检查的实施情况。对乳腺癌死亡率的预期影响需要10年或更长时间才能完全显现，并且只有在一系列更短期的终点得到满足时才会发生。来自瑞典两国随机试验的数据提供了应该达到的目标，遵循初始邀请的依从性的逻辑进展，患病率筛查时的患病率和分期分布，初始筛查后的间隔期癌症的发生率，后期筛查试验时的发病率和分期分布，后期试验后的间隔期癌症的发生率，晚期癌症的绝对发病率，以及乳腺癌的死亡率。出于评价目的，诊断时分期的历史数据是可取的;这表明，肿瘤大小可能是大多数情况下最相关的变量。
It is important that the introduction of breast screening is closely monitored. The anticipated effect on breast cancer mortality will take 10 years or more fully to emerge, and will only occur if a succession of more short-term end points are met. Data from the Swedish two-country randomised trial provide targets that should be achieved, following a logical progression of compliance with the initial invitation, prevalence and stage distribution at the prevalence screen, the rate of interval cancers after the initial screen, the pick-up rate and stage distribution at later screening tests, the rate of interval cancers after later tests, the absolute rate of advanced cancer and finally the breast cancer mortality rate. For evaluation purposes, historical data on stage at diagnosis is desirable; it is suggested that tumour size is probably the most relevant variable available in most cases.